Newsroom > Articles


The European Commission’s Innovation Radar has identified Medexprim as “Key Innovator” for its distinctive role in the H2020 PRIMAGE project.

The Primage project proposes an open cloud-based platform to support decision making in the clinical management of two paediatric cancers (Neuroblastoma and the Diffuse Intrinsic Pontine Glioma). It involves internationally recognized researchers in in-silico technologies and clinical experts in pediatric cancer, as well as 16 European partners.

The “Platform for the collection, exploration and analysis of clinical data” developed by the Primage partners has been identified by the European Commission Innovation Radar as a market ready innovation with a high potential of innovation. This platform implements the latest advancements in imaging biomarkers and in-silico modelling of tumour growth towards a personalised diagnosis, prognosis and therapies follow-up.

Karine Seymour, Chief Innovation Officer of Medexprim: “In PRIMAGE, Medexprim implemented solutions at hospitals to streamline the process of extracting and pseudonymizing medical images and associated clinical data using EUPID services (, significantly reducing the required time for people in charge of the data collection and guaranteeing full traceability. We are also implementing an image quality check module on the PRIMAGE platform.”

Romain Cazavan, CEO: “This recognition of our expertise at the European level validates our ability to provide hospitals with high-performance tools to enhance high-quality data. It also validates our ability to generate relevant imaging biomarkers, useful for researchers and physicians. Our ambition is to be the European leader in the extraction of Real-World evidence in full compliance with GDPR all over Europe, towards better patient care.”

French version of the PR

About Medexprim:

Medexprim is Europe’s leading provider of secure imaging and clinical data extraction to accelerate medical research. As a real-world data specialist, we build bridges between leading academic hospitals and pharmaceutical, AI and medical device companies. In compliance with the GDPR, we help hospitals drive their own clinical research strategy and extract value from their data, through our software and services designed with and for clinicians. We provide our partners with secure access to regulatory-grade data. Medexprim aims to build multicentric disease-specific data lakes to serve oncology, neurology and cardiology. We help solve the “one patient, one disease, one treatment” equation to develop precision medicine for better care.

LinkedIn Romain Cazavan

Medexprim Press contact: Anne-Sophie Labeta

3 questions to Coralie Carron

As a Ph.D. holder in Cellular and Molecular Biology, Coralie Carron assumes the pivotal…

CIAN: Cohort Imaging Analytics Network

Medexprim enables the aggregation, curation and enrichment of multicentric and multimodal cohorts of Real-World…

💡Scientific Insights – Read Samuel Boucher’s Take on the future…

Medexprim’s researchers and engineers contribute daily to the advancement of scientific research. Our researchers…

PR – Medexprim partners with Avicenna.AI to help validate their…

Medexprim, the European leader in multimodal Real-World datasets for clinical research, is pleased to…